智通财经网·2025-10-15 07:15Core Viewpoint - Bank of America Securities expects Alibaba Health (00241) to exceed market consensus for the fiscal year ending March 2024, raising revenue growth forecast by 4 percentage points to 14% and adjusted net profit growth forecast by 10 percentage points to 30% [1] Financial Performance - The adjusted net profit forecast for Alibaba Health has been increased by 8% for both the current and next fiscal years [1] - The expected compound annual growth rate (CAGR) of free cash flow from fiscal year 2024 to 2031 has been raised from 42% to 45% [1] Target Price and Rating - The target price for Alibaba Health has been raised from HKD 5.5 to HKD 6.56, with a reiterated "Buy" rating [1] Growth Drivers - Key drivers for Alibaba Health's better-than-expected performance include strong sales during the 618 shopping festival and accelerated investments by parent company Alibaba Group (09988) in fast e-commerce, which has increased traffic to Taobao and Tmall, benefiting Alibaba Health [1] - Increased online penetration of pharmaceutical sales, rising advertising expenditures from merchants and pharmaceutical brands have also contributed to the profit margin improvement for Alibaba Health [1]